SG Americas Securities
ADMA icon

SG Americas Securities’s ADMA Biologics ADMA Stock Holding History

SG Americas Securities’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$693K Buy
82,815
+12,655
+18% +$115K ﹤0.01% 2132
2026
Q1 		$632K Buy
70,160
+9,908
+16% +$156K ﹤0.01% 2049
2025
Q4 		$1.1M Buy
+60,252
New +$1.02M ﹤0.01% 1936
2025
Q3 		– Sell
-9,031
Closed -$164K – 3354
2025
Q2 		$164K Buy
9,031
+419
+5% +$8.54K ﹤0.01% 2381
2025
Q1 		$171K Buy
8,612
+2,058
+31% +$35.6K ﹤0.01% 2641
2024
Q4 		$112K Sell
6,554
-37,638
-85% -$708K ﹤0.01% 2645
2024
Q3 		$883K Sell
44,192
-319,550
-88% -$4.97M ﹤0.01% 1181
2024
Q2 		$4.07M Buy
363,742
+352,320
+3,085% +$2.96M 0.02% 646
2024
Q1 		$75K Sell
11,422
-81,814
-88% -$447K ﹤0.01% 2632
2023
Q4 		$421K Buy
93,236
+75,213
+417% +$278K ﹤0.01% 1586
2023
Q3 		$65K Buy
+18,023
New +$69.4K ﹤0.01% 2886
2023
Q2 		– Sell
-58,507
Closed -$194K – 2228
2023
Q1 		$194K Buy
58,507
+29,327
+101% +$101K ﹤0.01% 2434
2022
Q4 		$113K Sell
29,180
-113,291
-80% -$349K ﹤0.01% 2638
2022
Q3 		$346K Buy
142,471
+96,048
+207% +$230K ﹤0.01% 1870
2022
Q2 		$92K Buy
+46,423
New +$91.3K ﹤0.01% 3147
2021
Q2 		– Sell
-18,968
Closed -$33K – 2817
2021
Q1 		$33K Sell
18,968
-4,242
-18% -$9.71K ﹤0.01% 3188
2020
Q4 		$45K Buy
+23,210
New +$48.8K ﹤0.01% 3152
2020
Q3 		– Sell
-118,200
Closed -$346K – 2650
2020
Q2 		$346K Sell
118,200
-7,560
-6% -$21.7K ﹤0.01% 2412
2020
Q1 		$362K Buy
+125,760
New +$435K ﹤0.01% 2089

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SG Americas Securities's ADMA Position: Q2 2026 in Review

SG Americas Securities increased its ADMA Biologics (ADMA) stake by 18% in Q2 2026, buying an estimated $115K and bringing the position to 82,815 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

SG Americas Securities first reported a position in ADMA in Q1 2020 and has held it in 19 quarters since. The position peaked at $4.07M in Q2 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • SG Americas Securities held 82,815 shares of ADMA Biologics worth $693K as of Q2 2026.
  • SG Americas Securities bought 12,655 ADMA Biologics shares in Q2 2026, an estimated $115K.
  • ADMA Biologics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2132 holding.
  • SG Americas Securities first reported a position in ADMA Biologics in Q1 2020 and has held it in 19 quarters since.
  • SG Americas Securities's ADMA Biologics position peaked at $4.07M in Q2 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.